Study Title

68Ga-grazytracer PET/CT for Early Assessment of Response to Neoadjuvant Immunotherapy in Resectable NSCLC

Study Details

Description:

The purpose of this study is to explore the effectiveness of 68Ga-grazytracer PET/CT in early evaluation of neoadjuvant immunotherapy response in resectable NSCLC.

Sponsor:

Ruijin Hospital

Contacts:

Hecheng Li, MD, PHD

lihecheng2000@hotmail.com

021-74370045

Government Study Link:

NCT06756217 - Click here to see study on

ClinicalTrials.gov

Drug Details

68Ga-grazytracer
Isotope(s):
    GALLIUM-68
    Radioisotope: Ga-68
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 68 minutes
    Decay Mode: POSITRON β+ (88.9%), GAMMA, ELECTRON CAPTURE (8.7%)
    Energy: Beta: max 1.9 MeV Gamma 1.1 MeV, 511 keV
    Range: N/A
    Decay Daughters: Zn68 (Stable)
    Status: FDA Approvals: NETSPOT® (2016), LOCAMETZ® (2022), ILLUCIX® (2021)
  • GALLIUM-68
Target(s):
  • Granzyme B

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468